• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Amniotics

Less than 1K followers

Amniotics develops and manufactures stem cell therapies in our own GMP certified facility. Amniotics was born out of the discovery of a novel source of stem cells in full-term amniotic fluid. Based on a decade of research at the internationally recognized Lund University Stem Cell Center and Hospital, the company is pioneering the harvesting and propagation of tissue-specific neonatal quality mesenchymal stem cells (MSC). The company is listed at Nasdaq First North Growth Market in Stockholm.

Read more
All
Research
Press releases
ShowingAll content types

Regulatory press release23.09.2024 klo 14.30

The Swedish Companies Registration Office has authorised the implementation of the merger plan between Magle group and Amniotics

Amniotics
Press release20.08.2024 klo 14.27

Redeye: Amniotics H1 2024 - Merger with Magle

Amniotics
Regulatory press release06.08.2024 klo 11.45

Amniotics receives conditional approval to delist from Nasdaq First North Growth Market

Amniotics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release06.08.2024 klo 09.45

Amniotics applies for delisting from Nasdaq First North Growth Market conditional upon completion of the merger with Magle Group

Amniotics
Regulatory press release01.07.2024 klo 18.30

Amniotics publishes merger document regarding the merger with Magle Group

Amniotics
Regulatory press release30.05.2024 klo 21.05

Statement from the Board of Directors of Amniotics regarding the merger with Magle Group

Amniotics
Regulatory press release30.05.2024 klo 21.00

Magle Group and Amniotics merge to create a leader in high-quality life-changing healthcare innovations with a broadened CDMO offering

Amniotics
Regulatory press release21.05.2024 klo 22.50

Amniotics secures continued short-term capital needs by extending loan agreement and continued services under service agreement

Amniotics
Regulatory press release22.03.2024 klo 08.40

Statement from the Board of Directors of Amniotics regarding the public offer from Magle Chemoswed

Amniotics
Regulatory press release21.03.2024 klo 19.00

Amniotics secures short-term capital needs by extending loan agreement and entering into a service agreement

Amniotics
Regulatory press release11.03.2024 klo 17.00

Amniotics announces the outcome of the exercise of warrants series TO 3

Amniotics
Regulatory press release26.02.2024 klo 09.30

The exercise period for warrants series TO 3 in Amniotics begins today

Amniotics
Press release26.02.2024 klo 08.57

Redeye: Amniotics Q4 2023 - Investigator-sponsored trial in lung transplantation needs funding

Amniotics
Regulatory press release22.02.2024 klo 16.05

Amniotics AB (publ) Report for the fourth quarter 2023.

Amniotics
Press release21.12.2023 klo 15.16

Information about the Annual General Meeting and appointed Nomination Committee of Amniotics

Amniotics
Regulatory press release14.12.2023 klo 12.20

Amniotics receives orphan designation for PulmoStem® from the European Commission for the Treatment of Primary Graft Dysfunction following Lung Transplantation

Amniotics
Press release28.11.2023 klo 09.30

Redeye: Amniotics Q3 2023 - Rights Issue Foundation for Lung Transplantation Study

Amniotics
Regulatory press release27.11.2023 klo 09.00

Amniotics AB (publ) Report for the third Quarter 2023

Amniotics
Press release23.11.2023 klo 13.00

Renewed GMP certification

Amniotics
Regulatory press release20.11.2023 klo 16.40

Amniotics receives positive opinion on orphan designation for PulmoStem® from the European Medicines Agency for the Treatment of Primary Graft Dysfunction following Lung Transplantation

Amniotics